AngioDynamics, Inc. $ANGO Shares Acquired by Lazard Asset Management LLC

Lazard Asset Management LLC grew its holdings in AngioDynamics, Inc. (NASDAQ:ANGO) by 1,328.2% in the 1st quarter, HoldingsChannel reports. The firm owned 154,578 shares of the medical instruments supplier’s stock after purchasing an additional 143,755 shares during the quarter. Lazard Asset Management LLC’s holdings in AngioDynamics were worth $1,758,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Paradigm Capital Management Inc. NY lifted its holdings in AngioDynamics by 5.9% during the 1st quarter. Paradigm Capital Management Inc. NY now owns 718,200 shares of the medical instruments supplier’s stock worth $8,166,000 after buying an additional 40,000 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its stake in shares of AngioDynamics by 0.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 758,450 shares of the medical instruments supplier’s stock worth $8,624,000 after acquiring an additional 5,509 shares in the last quarter. Inceptionr LLC purchased a new stake in shares of AngioDynamics during the first quarter worth $115,000. Cetera Investment Advisers acquired a new stake in shares of AngioDynamics in the first quarter valued at $562,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of AngioDynamics by 3.5% in the first quarter. Dimensional Fund Advisors LP now owns 948,815 shares of the medical instruments supplier’s stock valued at $10,786,000 after acquiring an additional 32,476 shares in the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

AngioDynamics Stock Performance

NASDAQ:ANGO opened at $15.17 on Tuesday. The stock has a 50-day simple moving average of $12.87 and a 200-day simple moving average of $11.55. The stock has a market cap of $626.98 million, a P/E ratio of -17.44 and a beta of 0.33. AngioDynamics, Inc. has a 1 year low of $8.36 and a 1 year high of $15.41.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.04. The firm had revenue of $86.61 million during the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, equities research analysts predict that AngioDynamics, Inc. will post -0.27 EPS for the current year.

Insider Activity at AngioDynamics

In related news, SVP Warren Nighan, Jr. sold 23,370 shares of AngioDynamics stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the sale, the senior vice president directly owned 64,745 shares in the company, valued at $953,046.40. This trade represents a 26.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 6.00% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research analysts recently commented on ANGO shares. Canaccord Genuity Group boosted their target price on AngioDynamics from $16.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Freedom Capital upgraded AngioDynamics to a “strong-buy” rating in a research note on Monday, April 6th. Zacks Research downgraded AngioDynamics from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 16th. Finally, HC Wainwright upped their target price on shares of AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, AngioDynamics currently has an average rating of “Hold” and a consensus price target of $19.50.

AngioDynamics Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.